Abstract: A method for obtaining leucocyte components from human blood including (A) a first step for fracturing the cell membrane of leucocytes of human blood by using a freezing and defrosting method, a supersonic application, laser irradiation, an osmotic pressure changing method, a vacuum chamber, or the like and (B) a second step for separating and collecting the leucocyte-components containing the leucocytes with fractured cell membranes from the blood liquid resulted from the first step by way of a centrifugal precipitation technique or an electrophoresis technique. After being separated and collected, the leucocyte components are, respectively, subjected to various therapeutic tests using blood samples collected from patients suffering from various diseases to determine the therapeutic effects.

Abstract: The use of interleukin 7 or T cells pre-incubated in the presence of IL-7 for preparing a drug or pharmaceutical composition for treating an auto-immune disease, particularly an auto-immune disease induced by a defect in CD4+ T cell immunoregulation, is disclosed.

Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

Abstract: Vasospastic disorders are treated by administering to the patient an aliquot of autologous blood which has been subjected simultaneously to heat, ultraviolet irradiation and oxidative environment so as to render the blood aliquot capable of generating in the patient's blood stream after administration a population of stimulated leukocytes having upregulated expression of CD25 cell surface markers, along with an enhancement of endothelial function in the patient.

Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.

Abstract: The invention provides a method of determining whether a compound alleviates vasoconstriction-independent nerve pain mediated by endothelin-1 (ET-1). The method involves (i) determining whether the compound has the ability to inhibit a vasoconstriction-independent ET-1 action, and, if the compound has the inhibitory ability, then ii) determining whether the compound reduces vasoconstriction-independent nerve pain by testing the compound in human patients suffering from pain mediated by the vasoconstriction-independent ET-1 action. The invention also includes a method of determining whether a compound alleviates pain caused by nerve injury in human patients. The method involves (i) determining whether the compound has the ability to inhibit an inflammatory leukocyte response, and, if the compound has the inhibitory ability, then (ii) testing the compound in human patients suffering from pain caused by nerve injury to determine whether the compound alleviates the pain.

Abstract: A method of treating or preventing atherosclerosis in a mammalian subject comprises: (a) extracting the aliquot of blood from the subject; (b) treating the aliquot of blood ex vivo with at least one stressor selected from the group consisting of an oxidizing agent, ultraviolet radiation and elevated temperature; and (c) administering the aliquot of blood treated in step (b) to the subject. Preferably, the aliquot has a volume of from about 0.01 ml to about 400 ml and is treated simultaneously by ozone gas and ultraviolet radiation at a temperature of from 37-55° C.

Abstract: A hematology control composition and method of making the composition is provided. The control employs a plurality of components including a synthetic plasma component, a red blood cell component, a platelet component and a leukocyte component. The leukocyte component includes at least one subpopulation having particles derived from other than white blood cells.

Abstract: An assay method for detecting the response or activation of cells, including lymphocytes, and a method for detecting immunological sensitization in a subject, which involves the introduction of cell-activating substance which causes an enzyme of the cells to become available for reaction, and the measurement of the enzymatic reaction using a substrate which generates a detectable product, and a kit for performing such assays.

Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

Abstract: A purified, soluble lymphocyte-derived antimicrobial protein that has a molecular weight of 16 kD on SDS-PAGE, is inactivated by heating at 56° C. for 30 minutes or by treatment with trypsin, is expressed by CD3−, CD2+ cytokine-stimulated cells', and is active against Gram positive or Gram-negative bacteria including Staphylococcus aureus.

Abstract: A method for the enrichment of dendritic cells from the peripheral blood of a mammal is described. Peripheral blood having mononuclear cells from a mammal is provided. The mononuclear cells are separated from the peripheral blood. The mononuclear cells are separated into a first cell population having substantially lymphocytes and a second cell population having substantially myeloid cells. The myeloid cells are separated into a third cell population having substantially monocytes and a fourth cell population having substantially dendritic cells. Also described are purified dendritic cell populations, vaccine compositions and methods for the treatment of cancer using dendritic cells, and kits useful for the enrichment of dendritic cells from blood.

Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).

Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Abstract: Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.

Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.

Abstract: Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3 antibody, the lymphocytes derived from the cord blood is prepared by segregating lymphocytes from the cord blood and proliferating the segregated lymphocytes directly in vitro or segregating monocytes from cord blood and proliferating the monocytes in vitro. Also, the cord blood-derived activated lymphocytes can be effectively used for preventing recurrence of the diseases and promoting the take of stem cells or other organs.

Abstract: A method of quality control to diagnose the cause of a malfunction of an instrument. The method uses measurements of the physical property of a sample to diagnose the cause of a malfunction of an instrument. The spatial position of a control product sample is analyzed. Alternatively, the spatial position of a statistically significant number of patient blood samples can be used. The method enables the monitoring of an instrument for problems associated with debris and noise caused by red cell lysis inefficiency; instrument reagents pump volume settings; instrument laser alignments; instrument gain settings; and flow noise caused by partial plugs, residual plugs or other flow problems. The method provides a more specific indication of the type and cause of an instrument malfunctioning than non specific flagging provided by prior art methods.

Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.

Abstract: A process is disclosed for the production of immune-genetically active suspensions of which the initial substances are fluids or tissues from the human or animal body. Autohemotherapy, immune-stimulatory and/or immune-suppressive effects are employed. The suspensions thus produced can be used as pooled sera as desired.

Abstract: A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected containers; centrifuging the container system containing said blood so as to separate the blood in various fractions including a plasma fraction; transferring at least part of the plasma fraction to said second container of the container system; subjecting the plasma fraction in said second container to a low temperature so as to obtain a precipitate comprising tissue repair promoting substances; concentrating said precipitate in said second container so as to obtain a first fraction comprising a major part of the non-precipitated material, and a second fraction comprising at least the major part of the precipitate and a minor part of the non-precipitated material; and separating said second fraction comprising the tissue repair pro

Abstract: A method for controlling immune reactions to a foreign tissue or a foreign cell in a recipient host mammal to enhance tolerance of the recipient host mammal towards a grafted foreign tissue or a grafted foreign cell. This method involves administering a transferrin and a foreign tissue or a foreign cell antigen from the same genetic donor to a previously immunosuppressed recipient host mammal.

Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

Abstract: This invention is directed to methods of manufacturing implantable biocompatible cell encapsulation devices, wherein the cell encapsulation devices have a jacket made of a permeable, biocompatible material that is loaded with a core made of a reticulate foam scaffold having interconnected pores, with cells that are dispersed in the interconnected pores.

Abstract: A method for the enrichment of dendritic cells from the peripheral blood of a mammal is described. Peripheral blood having mononuclear cells from a mammal is provided. The mononuclear cells are separated from the peripheral blood. The mononuclear cells are separated into a first cell population having substantially lymphocytes and a second cell population having substantially myeloid cells. The myeloid cells are separated into a third cell population having substantially monocytes and a fourth cell population having substantially dendritic cells. Also described are purified dendritic cell populations, vaccine compositions and methods for the treatment of cancer using dendritic cells, and kits useful for the enrichment of dendritic cells from blood.

Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).

Abstract: Therapeutic methods using a purified isolated human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the patient is administered mitogenically stimulated lymph node lymphocytes or the supernatant therefrom. The lymph node lymphocytes are patient excised lymph node lymphocytes enriched in tumor reactive cells, such as CD4+ tumor reactive cells. Radiolabeled locators (e.g., antibodies) can be used along with a portable radiation detector to intraoperatively determine which lymph nodes bear lymph node lymphocytes enriched in tumor reactive cells. The patient excised lymph node lymphocytes enriched in tumor reactive cells then are subjected to mitogenic stimulation for their expansion and administration to the patient.

Abstract: The present invention provides a composition comprising a BPI Protein and an anionic compound which composition exhibits (1) no bacterial activity and (2) endotoxin neutralizing activity. Also, this invention provides methods for using BPI Proteins.

Abstract: The present invention provides a non-human genetically immunodeficient mammal the peripheral blood of which contains a non-lethal percent of T-cells of human origin which is at least 20% as well as a non-human genetically immunodeficient mammal having a lethal percent of T-cells of human origin in the peripheral blood which is at least 60%. Also provided is a method of screening a substance for anti-HIV activity comprising obtaining a non-human genetically immunodeficient mammal having a lethal percent of human T-cells in the peripheral blood which is at least 60%; infecting the mammal with an amount of HIV sufficient to rescue the mammal from death from the effects of the lethal percent of human T-cells; administering the substance to the mammal; and determining if the substance kills the mammal by inhibiting the rescue of the mammal by HIV, the death of the mammal indicating a substance having anti-HIV activity.

Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

Abstract: Reference controls comprised of aldehyde-fixed white blood cells stabilized red blood cells and simulated blood platelets exhibiting a white blood cell histogram profile that is substantially that of whole blood are obtained by the addition of a lipoprotein to the control and an antioxidant to inhibit lysis of stabilized red blood cells by said lipoprotein.

Abstract: The present invention relates to a method of stimulating the proliferation and appropriate cell maturation of a variety of different cells and tissues in three-dimensional cultures in vitro using TGF-.beta. in the culture medium. In accordance with the invention, stromal cells, including, but not limited to, chondrocytes, chondrocyte-progenitors, fibroblasts, fibroblast-like cells, umbilical cord cells or bone marrow cells from umbilical cord blood are inoculated and grown on a three-dimensional framework in the presence of TGF-.beta.. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc.

Abstract: Cyanide-free reagents for the determination of hemoglobin and leukocytes present in a blood sample contain an aqueous solution of at least one quaternary ammonium salt, preferably selected from the group of alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts or alkylpyridium salts consisting of tetradecyltrimethyl ammonium bromide (TTAB), dodecyltrimethyl ammonium chloride, cetyltrimethyl ammonium bromide, hexadecyltrimethyl ammonium bromide and benzalkonium chlorides, and hydroxylamine salts, especially hydrochloride, sulfate and phosphates and other acid salts. The method involves mixing the reagent with a diluent- diluted blood sample, presenting it to an absorbance spectrophotometer and measuring the resulting optical density as an indicator of hemoglobin concentration. This cyanide-free reagent could be used solely for hemoglobin determinations, or , it can also be used in leukocyte counting and sizing using hematology instrumentation.

Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).

Abstract: Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.

Abstract: The present invention relates to compositions useful in the stimulation of hair growth. These compositions comprise a conditioned medium obtained from a cell culture of human mononuclear cells or a conditioned or extracted medium obtained from a cell culture of mammalian normal or transformed cells or cancer cells.

Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

Abstract: A cyanide-free lytic reagent composition and method for measuring the total hemoglobin concentration in a blood sample, for counting the number of leukocytes and for deferential counting of leukocyte subpopulations are described. The cyanide-free lytic reagent composition cotains a quaternary ammonium salt or a pyridinium salt to lyse erythrocytes and release hemoglobin, and an organic ligand including triazole and its derivatives, tetrazole and its derivatives, alkaline metal salts of oxonic acid, melamine, aniline-2-sulfonic acid, quinaldic acid, 2-amino-1,3,4-thiadiazole, triazine and its derivatives, urazole, DL-pipecolinic acid, isonicotinamide, anthranilonitrile, 6-aza-2-thiothymine, 3-(2-thienyl)acrylic acid, benzoic acid and alkali metal and ammonium salts of benzoic acid, and pyrazine and its derivatives to form a stable chromogen with hemoglobin, and a salt to adjust conductivity of the reagent for impedance measurement.

Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

Abstract: A process for an induction culture of a cytotoxic T lymphocyte having cell killing activities against a tumor cell which comprises the step of coculturing a tumor tissue containing said tumor cell and a lymphocyte of autologous peripheral blood obtained from a subject from which the tumor tissue is derived. The process is convenient since no separation and pure culture of tumor cells is required. The resulting cytotoxic T lymphocyte cells are useful for clinical treatments of tumors, e.g. adoptive immunotherapies.

Abstract: This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.

Abstract: The invention describes the preparation of preserved, non-infectious control cells. The control cells are prepared by modification, activation or otherwise changing selected normal leukocyte cells, tissue culture cells or zenogenic transplants in immunosuppressed animals to have characteristics of abnormal cells or by the addition of cells from an established cell line, which has been similarly modified or activated, to a normal leukocyte population. The preferred method of preserving the control cells is by lyophilization using an isotonic 10% trehalose solution.

Abstract: A method of treating animals, particularly rhea and ostrich chicks with adipose depletion, by injection with an oil derived from rhea or ostrich adipose or by injection with an active component of the oil that increases anti-inflammatory capabilities and phospholipid formation.

Abstract: This invention provides a method of using modified human cytotoxic TALL-104 cell line, which is characterized by activity against tumor cells. More particularly, the method comprises treating bone marrow cells of an immunosuppressed mammalian patient with the modified TALL-104 cell line and reinjecting the treated bone marrow into the patient, as a treatment of hematological malignancies. Also provided are effective and safe methods of use of the modified cells in the manufacture of a veterinary composition for adoptive therapy of canine lymphoma and feline leukemias.

Abstract: Methods and pharmaceutical compositions for improving the effectiveness of radiation therapy for treating a subject having an internal solid tumor malignancy are disclosed. The methods include irradiating the tumor to release tumor-derived antigens in vivo, preparing a cellular vaccine including the isolated antigens admixed with a preparation of altered antigen presenting cells and administering the cellular vaccine to the subject. In the preferred embodiments, the antigen presenting cells are leukocytes that have been photochemically altered by subjecting the cells to photopheresis.

Abstract: Disclosed are a kit, composition and method for cell separation. The kit includes a centrifugable container and an organosilanized silica particle-based cell separation suspension suitable for density gradient separation, containing a polylactam and sterilized by treatment with ionizing radiation. The composition includes a silanized silica particle-based suspension for cell separation which contains at least 0.05% of a polylactam, and preferably treated by ionizing radiation. Also disclosed is a method of isolating rare blood cells from a blood cell mixture.

Abstract: A method for inhibiting rejection by a recipient animal of a transplanted tissue, said method comprising modifying, eliminating, or masking an antigen which, when present on the surface of a cell of said tissue, is capable of causing a T-lymphocyte-mediated response in said animal, to inhibit antigen-mediated interaction between said cell and a T-lymphocyte of said animal without causing lysis of said cell.

Abstract: The present invention relates to methods of therapeutic or prophylactic treatment of connective tissue diseases by systemic or local delivery of a nucleic acid sequence to a mammalian host. Expression of the nucleic acid sequence results in the systemic delivery of a biologically active protein or peptide which acts to antagonize inflammatory, hypertrophic and erosive phenomenon associated with connective tissue disease. Systemic delivery of such gene products results in sustained treatment of connective tissue diseases such as rheumatoid arthritis and systemic lupus erythematosus.